Myopathy associated with epsilon-aminocaproic acid (EACA) therapy

Abstract
The association of myopathy with epsilon-aminocaproic acid (EACA) treatment after subarachnoid hemorrhage in 2 cases is reported. Clinical and laboratory findings and possible mechanisms are discussed in light of the known pharmacology of the drug. Recovery ensues if EACA treatment is terminated as soon as myopathy appears.